Oncotarget

Research Papers:

Autoimmune hematological diseases following haploidentical donor hematopoietic stem cell Transplant compared with matched sibling and unrelated donor

Weiran Lv, Zhiping Fan, Fen Huang, Na Xu, Li Xuan, Guopan Yu, Qianli Jiang, Hongsheng Zhou, Ren Lin, Xin Zhang, Jing Sun and Qifa Liu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:26505-26514. https://doi.org/10.18632/oncotarget.15710

Metrics: PDF 785 views  |   HTML 1023 views  |   ?  


Abstract

Weiran Lv1, Zhiping Fan1, Fen Huang1, Na Xu1, Li Xuan1, Guopan Yu1, Qianli Jiang1, Hongsheng Zhou1, Ren Lin1, Xin Zhang1, Jing Sun1, Qifa Liu1

1Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515 China

Correspondence to:

Qifa Liu, email: liuqifa628@163.com

Keywords: autoimmune hematological diseases, risk factors, treatment, donors, allogeneic hematopoietic stem cell transplantation

Received: October 17, 2016     Accepted: February 10, 2017     Published: February 24, 2017

ABSTRACT

Autoimmune hematological diseases (AHDs) occur more frequently than other autoimmune complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and are often refractory to treatment. This study was to analyze the incidence and risk factors of AHDs as well as their response to treatment . Four hundred and forty-five adult malignant hematopoietic disorders underwent allo-HSCT were enrolled in this retrospective study, including 124 haploidentical donor (HRD), 140 unrelated donor (MUD) and 181 HLA-matched sibling donor (MSD) transplants. Twelve patients developed AHDs, including 6 autoimmune hemolytic anemia and 6 Evans syndrome. Evans syndrome all occurred in HRD transplants. The 3-year cumulative incidence of AHDs was 4.0 ± 1.3%, and HRD had higher incidence than MUD (8.7 ± 3.0% vs 1.8 ± 1.2%, P = 0.012) and MSD (8.7 ± 3.0% vs 3.5 ± 2.6%, P = 0.004 ). The steroids combined with Cyclosporine A were acted as the first line treatment, and the response rate was 73%. No patients experienced recurrence at a median follow up of 313 days after stopping treatment. HRD transplants (vs MUD: HR, 5.87; CI, 1.24 to 27.73; p = 0.026 and vs MSD: HR, 7.70; CI, 1.63 to 36.44; P = 0.010) and concurrent chronic graft versus host disease (HR, 3.76; CI, 1.18 to 11.92; P = 0.025) were risk factors for AHDs.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15710